CURRENT RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF PULMONARY ARTERIAL HYPERTENSION


Cite item

Full Text

Abstract

Pulmonary hypertension is a rather frequent pathophysiological and hemodynamic condition detectable in many clinical situations including pulmonary and cardiac diseases. Pulmonary arterial hypertension (pAH) is a specific clinical group of severe and rare diseases with similar morphological, hemodynamic and therapeutic characteristics. PAH diagnosis is confirmed by catheterization of the right heart. Special pharmacotherapy has been developed of late for PAH-oriented treatment. PAH is a progressive disease and therefore demands continuous monitoring and escalation of pharmacotherapy if therapeutic targets fail to be achieved with monotherapy. Combined treatment of PAH seems to be optimal now.

About the authors

S N Avdeev

Research Institute of Pulmonology

Email: serg_avdeev@list.ru
д-р мед. наук, проф., рук. клинического отдела

References

  1. Galie N., Hoeper M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Heart J. 2009; 30: 2493—2537.
  2. Galie N., Hoeper M. M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2009; 34: 1219—1263.
  3. Macchia A., Marchioli R., Marfisi R. et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am. Heart J. 2007; 153: 1037—1047.
  4. Hatano S., Strasser T. Primary pulmonary hypertension: Report of a WHO meeting. Geneva: WHO; 1975.
  5. D’Alonzo G. E., Barst R. J., Ayres S. M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 1991; 115: 343—349.
  6. Kovacs G., Berghold A., Scheidl S. et al. Pulmonary arterial pressure during rest and exercise in healthy subjects. A systematic review. Eur. Respir. J. 2009; 34: 888—894.
  7. Badesch B. D., Champion H. C., Gomez-Sanchez M. A. et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009; 54: S55—S56.
  8. Naeije R., Melot C., Niset G. et al. Mechanisms of improved arteria oxy genation after peripheral chemoreceptor stimulation during hypoxic exercise. J. Appl. Physiol. 1993; 74: 1666—1671.
  9. Oudiz R. J. Pulmonary hypertension associated with left-sided heart disease. Clin. Chest Med. 2007; 28: 233—241.
  10. Galie N., Palazzini M., Manes A. Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed. Eur. Respir. J. 2010; 36: 986—990.
  11. Mukerjee D., St George D., Knight C. et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004; 43: 461—466.
  12. Vachiéry J. L., Brimioulle S., Crasset V. et al. False-positive diagnosis of pulmonary hypertension by Doppler echocardiography. Eur. Respir. J. 1998; 12: 1476—1478.
  13. Hachulla E., Gressin V., Guillevin L. et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthr. and Rheum. 2005; 52: 3792—3800.
  14. Sitbon O., Lascoux-Combe C., Delfraissy J. F. et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am. J. Respir. Crit. Care Med. 2008; 177: 108—113.
  15. Simonneau G., Robbins I., Beghetti M. et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2009; 54: S43—S54.
  16. Gabbay E., Yeow W., Playford D. Pulmonary arterial hypertension (PAH) is an uncommon cause of pulmonary hypertension (PH) in an unselected population: the Armadale echocardiography study. Am. J. Respir. Crit. Care Med. 2007; 175: A713—A715.
  17. Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 2006; 173: 1023—1030.
  18. Peacock A. J., Murphy N. F., McMurray J. J. V et al. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 2007; 30: 104—109.
  19. Torbicki A., Perrier A., Kstantinides S. et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur. Heart J. 2008; 29: 2276—2315.
  20. McLaughlin V. V., Archer S. L., Badesch D. B. et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250—2294.
  21. Sitbon O., Humbert M., Jaïs X. et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105—3111.
  22. Barst R. J., Gibbs S. R., Ghofrani H. A. et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009; 54: S78—S84.
  23. Galié N., Torbicki A., Barst R. et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart J. 2004; 25: 2243—2278.
  24. Bautet K., Montani D., Jaïs X. et al. Therapeutic advances in pulmonary arterial hypertension. Ther. Adv. Respir. Dis. 2008; 2: 249—265.
  25. Чазова И. Е., Мартынюк Т. Идиопатическая (первичная) легочная гипертензия. Респираторная медицина — руководство под редакцией акад. РАМН А. Г. Чучалина. Гэотар-Медиа 2007; 2: 133—144.
  26. Badesch D. B., Abman S. H., Simanneau G. et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917—1928.
  27. Frishman W. H., Landau A., Cretkovic A. Combination drug therapy with calcium-channel blockers in the treatment of systemic hypertension. J. Clin. Pharmacol. 1993; 33: 752—755.
  28. Pitt B., Zannad F., Remme W. J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999; 341: 709—717.
  29. Barst R. J., Rubin L. J., Long W. A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 1996; 334: 296—302.
  30. McLaughlin V. V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477—1482.
  31. McLaughlin V. V. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur. J. Clin. Invest. 2006; 36 (Suppl. 13): 10—15.
  32. Sitbon O., McLaughlin V. V., Badesch D. B. et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60: 1025—1030.
  33. Channick R. N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: randomised placebo-controlled study. Lancet 2001; 358: 1119—1123.
  34. Rubin L. J., Badesch D. B., Barst R. J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2002; 346: 896—903.
  35. Galiè N., Olschewski H., Oudiz R. J. et al. Ambrisentan for the treat ment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010—3019.
  36. Galie N., Brundage B. H., Ghofrani H. A. et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894—2903.
  37. Galiè N., Ghofrani H. A., Torbicki A. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2005; 353: 2148—2157.
  38. Barst R. J., Langleben D., Frost A. et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2004; 169: 441—447.
  39. Barst R. J., Langleben D., Badesch D. et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. 2006; 47: 2049—2056.
  40. Galiè N., Rubin L. J., Hoeper M. M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093—2100.
  41. Humbert M., Barst R. J., Robbinsl. M. et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J. 2004; 24: 353—359.
  42. Hoeper M. M., Leuchte H., Halank M. et al. Combining inhaled ilo-prost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2006; 28: 691—694.
  43. Simonneau G., Rubin L. J., Galie N. et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann. Intern. Med. 2008; 149: 521—530.
  44. Hoeper M. M., Markevych I., Spikerkoetter E. et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur. Respir. J. 2005; 26: 858—863.
  45. Provencher S., Sitbon O., Humbert M. et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur. Heart J. 2006; 27: 589—595.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies